摘要
目的 探讨茯苓罗汉茶对脾湿痰阻型肥胖并伴有高脂血症患者的临床疗效。方法 将96例患者随机分为对照组和干预组，每组48例。对照组口服洛伐他汀片，干预组服用茯苓罗汉茶，两组均持续治疗30天。观察并比较两组患者临床疗效、中医证候评分、肥胖相关指标（腰围、BMI）和血脂异常相关指标（TC、TG、HDL-C、LDL-C）的变化。结果 干预组的临床总有效率为95.8%，显著优于对照组的79.2% (P<0.05)。干预组患者的脾湿痰阻中医证候评分、肥胖相关的腰围和BMI指数、高脂血症相关指标均有显著改善，并且改善幅度大于对照组。结论 茯苓罗汉茶可以有效改善脾湿痰阻型肥胖并伴有高脂血症患者的临床疗效，改善中医证候，降低腰围和BMI，调节血脂水平。
关键词： 茯苓罗汉茶；脾虚痰阻型；肥胖；高脂血症
Abstract
Objective To investigate the clinical efficacy of Fuling Luohan Tea in patients with spleen deficiency and phlegm stasis type obesity complicated by hyperlipidemia. Methods A total of 96 patients were randomly divided into a control group and an intervention group, with 48 patients in each group. The control group was treated with lovastatin tablets, while the intervention group received Fuling Luohan Tea. Both groups were treated continuously for 30 days. The clinical efficacy, Traditional Chinese Medicine (TCM) syndrome scores, obesity-related indicators (waist circumference, BMI), and hyperlipidemia-related indicators (TC, TG, HDL-C, LDL-C) were observed and compared between the two groups. Results The total clinical effective rate in the intervention group was 95.8%, significantly higher than the 79.2% in the control group (P<0.05). The TCM syndrome scores for spleen deficiency and phlegm stasis, obesity-related indicators (waist circumference and BMI), and hyperlipidemia-related indicators in the intervention group were all significantly improved, with a greater magnitude of improvement than in the control group. Conclusion Fuling Luohan Tea can effectively improve the clinical efficacy of patients with spleen deficiency and phlegm stasis type obesity complicated by hyperlipidemia, ameliorate TCM syndromes, reduce waist circumference and BMI, and regulate lipid levels.
Key words： Fuling Luohan tea; Spleen deficiency and phlegm stasis type; Obesity; Hyperlipidemia
参考文献 References
[1] Heidari S, Kahnooji M, Ayoobi F, et al. Relationship between metabolic syndrome and dietary diversity in the Rafsanjan cohort study[J]. Scientific Reports, 2025, 15(1): 10579.
[2] Zhang J, Zhu S, Liu C, et al. Global, regional and national burden of ischemic stroke attributed to high low-density lipoprotein cholesterol, 1990–2019: a decomposition analysis and age-period-cohort analysis[J]. Journal of Cerebral Blood Flow & Metabolism, 2024, 44(4): 527-541.
[3] 魏方志, 符慧伦, 李洋, 蒋欢, 李菁虹, 廖华蕊, 章红英, 王子良. 246 例高脂血症患者不同证型客观指标特征研究[J]. 中医学, 2025, 14(6): 2818-2825.
[4] Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China[J]. The lancet Diabetes & endocrinology, 2021, 9(6): 373-392.
[5] Wang Y, Zhao L, Gao L, et al. Health policy and public health implications of obesity in China[J]. The lancet Diabetes & endocrinology, 2021, 9(7): 446-461.
[6] 中国居民肥胖防治专家共识[J].中国预防医学杂志, 2022,23(05):321-339.
[7] 王馥婕, 马向华, 赵婷, 王瑾, 蔡金鑫, 戴倩倩. 肥胖与高尿酸血症、高脂血症的相关性[J]. 食品与营养科学, 2019, 8(3): 180-186.
[8] 中华人民共和国国家卫生健康委员会. 肥胖症诊疗指南（2024 年版）[Z]. 2024-10-14.
[9] 他汀不耐受的临床诊断与处理中国专家共识[J].中国循环杂志,2024,39(02):105-115.
[10] 危北海,贾葆鹏.单纯性肥胖病的诊断及疗效评定标准[J].中国中西医结合杂志,1998,(05):317-319.
[11] 诸骏仁,高润霖,赵水平,等.中国成人血脂异常防治指南(2016年修订版)[J].中国循环杂志,2016,31(10):937-953.
[12] 郑筱萸.中药新药临床研究指导原则[M].北京中国医药科技出版社,2002.
[13] 韩思婕,潘翔,朱芊芊,等.茯苓多糖调节2型糖尿病模型大鼠肝脏糖异生的机制研究[J].中国药房,2022, 33(13): 1581-1587.
[14] Cao S, Liu M, Han Y, et al. Effects of saponins on lipid metabolism: the gut–liver axis plays a key role[J]. Nutrients, 2024, 16(10): 1514.
[15] 方潇,丁晓萍,昝俊峰,等.茯苓皮化学成分及药理作用研究进展[J].亚太传统医药,2019,15(01):187-191.
[16] 田时秋,李依林,裴海鸾,等.高脂血症发病机制及药物治疗[J].生命的化学,2022,42(12):2237-2247.